Oncotarget

Research Papers:

The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis

Daniel Brungs _, Julia Chen, Morteza Aghmesheh, Kara L. Vine, Therese M. Becker, Martin G. Carolan and Marie Ranson

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23099-23109. https://doi.org/10.18632/oncotarget.15485

Metrics: PDF 1366 views  |   HTML 1977 views  |   ?  


Abstract

Daniel Brungs1,2,3,4, Julia Chen5, Morteza Aghmesheh1,3,4, Kara L. Vine1,2,4, Therese M. Becker4,6,7,8, Martin G. Carolan1,3,4, Marie Ranson1,2,4

1Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia

2School of Biological Sciences, University of Wollongong, Wollongong, Australia

3Illawarra Cancer Centre, Wollongong Hospital, Wollongong, Australia

4CONCERT-Translational Cancer Research Centre, New South Wales, Australia

5St George Cancer Centre, St George Hospital, Sydney, Australia

6Ingham Institute for Applied Medical Research, Liverpool Hospital, Australia

7School of Medicine, University of Western Sydney, Liverpool, Australia

8South Western Medical School, University of New South Wales, Liverpool, Australia

Correspondence to:

Daniel Brungs, email: Daniel.brungs@health.nsw.gov.au

Keywords: stomach neoplasms, gastrointestinal neoplasms, urokinase-type plasminogen activator, urokinase plasminogen activator

Received: November 30, 2016     Accepted: February 07, 2017     Published: February 18, 2017

ABSTRACT

Background: The urokinase plasminogen activation (uPA) system is a crucial pathway for tumour invasion and establishment of metastasis. Although there is good evidence that uPA system expression is a clinically relevant biomarker in some solid tumours, its role in gastroesophageal cancer is uncertain.

Results: We identified 22 studies encompassing 1966 patients which fulfilled the inclusion criteria. uPA, uPAR, or PAI-1 expression is significantly associated with high risk clinicopathological features. High uPA expression is associated with a shorter RFS (HR 1.90 95% 1.16–3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74–2.80, p < 0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI 1.82–2.69, p < 0.0001). High PAI-1 expression is associated with shorter RFS (HR 1.96 96% CI 1.07–3.58, p = 0.03) and OS (HR 1.84 95%CI 1.28–2.64, p < 0.0001). There was no significant association between PAI-2 expression and OS (HR 0.97 95%CI 0.48–1.94, p < 0.92) although data was limited.

Materials and Methods: We undertook a systematic review evaluating expression of uPA, urokinase plasminogen activator receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/SerpinB2) on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas. We performed a meta-analysis of clinicopathological associations, overall survival (OS) and recurrence free survival (RFS).

Conclusions: We conclude that the uPA system is a clinically relevant biomarker in primary gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1 associated with higher risk disease and poorer prognosis. This also highlights the potential utility of the uPA system as a therapeutic target for improved treatment strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15485